Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 74

1.

Evaluation of endocrine complications in beta-thalassemia intermedia (β-TI): a cross-sectional multicenter study.

Karimi M, Zarei T, Haghpanah S, Azarkeivan A, Kattamis C, Ladis V, Kattamis A, Kilinc Y, Daar S, Alyaarubi S, Khater D, Wali Y, Elshinawy M, Almadhani A, Yassin M, Soliman AT, Canatan D, Obiedat M, Al-Rimawi H, Mariannis D, Christodoulides C, Christou S, Tzoulis P, Campisi S, Di Maio S, De Sanctis V.

Endocrine. 2019 Dec 18. doi: 10.1007/s12020-019-02159-6. [Epub ahead of print]

PMID:
31853840
2.

Effect of quercetin on oxidative stress and liver function in beta-thalassemia major patients receiving desferrioxamine: A double-blind randomized clinical trial.

Sajadi Hezaveh Z, Azarkeivan A, Janani L, Shidfar F.

J Res Med Sci. 2019 Oct 25;24:91. doi: 10.4103/jrms.JRMS_911_18. eCollection 2019.

3.

Evaluation of Efficacy, Safety, and Satisfaction Taking Deferasirox Twice Daily Versus Once Daily in Patients With Transfusion-Dependent Thalassemia.

Karimi M, Haghpanah S, Bahoush G, Ansari S, Azarkeivan A, Shahsavani A, Bazrafshan A, Jangjou A.

J Pediatr Hematol Oncol. 2020 Jan;42(1):23-26. doi: 10.1097/MPH.0000000000001596.

PMID:
31568183
4.

The effect of quercetin on iron overload and inflammation in β-thalassemia major patients: A double-blind randomized clinical trial.

Sajadi Hezaveh Z, Azarkeivan A, Janani L, Hosseini S, Shidfar F.

Complement Ther Med. 2019 Oct;46:24-28. doi: 10.1016/j.ctim.2019.02.017. Epub 2019 Feb 26.

PMID:
31519283
5.

Novel variants in Iranian individuals suspected to have inherited red blood cell disorders, including bone marrow failure syndromes.

Neishabury M, Mehri M, Fattahi Z, Najmabadi H, Azarkeivan A.

Haematologica. 2020 Jan;105(1):e1-e4. doi: 10.3324/haematol.2019.216069. Epub 2019 May 16. No abstract available.

6.

The Role of Exercise Stress Echocardiography for Determination of Subclinical Cardiac Involvement in β-Thalassemia Major.

Parsaee M, Pouraliakbar H, Azarkeivan A, Ghadrdoost B, Behjati M.

Hemoglobin. 2019 Jan;43(1):34-37. doi: 10.1080/03630269.2019.1572620. Epub 2019 May 14.

PMID:
31084365
7.

Frequency of α-Globin Gene Triplications and Coinheritance with β-Globin Gene Mutations in the Iranian Population.

Abedini SS, Forouzesh Pour F, Karimi K, Ghaderi Z, Farashi S, Tavakoli Koudehi A, Javadi Pirouz H, Mobini Nejad SB, Azarkeivan A, Najmabadi H.

Hemoglobin. 2018 Jul;42(4):252-256. doi: 10.1080/03630269.2018.1526192. Epub 2018 Nov 19.

PMID:
30451045
8.

The effectiveness of sofosbuvir and daclatasvir in the treatment of hepatitis C in thalassaemia major patients and their effect on haematological factors.

Zamani F, Ajdarkosh H, Safarnezhad-Tameshkel F, Azarkeivan A, Keyvani H, Naserifar F, Vafaeimanesh J.

Indian J Med Microbiol. 2018 Apr-Jun;36(2):224-229. doi: 10.4103/ijmm.IJMM_18_90.

9.

Survival analysis of thalassemia major patients using Cox, Gompertz proportional hazard and Weibull accelerated failure time models.

Bakhshi E, Ali Akbari Khoei R, Azarkeivan A, Kooshesh M, Biglarian A.

Med J Islam Repub Iran. 2017 Dec 17;31:97. doi: 10.14196/mjiri.31.97. eCollection 2017.

10.

Comparative Evaluation of Biochemical and Hematological Parameters of Pre-Storage Leukoreduction during RBC Storage.

Ghezelbash B, Azarkeivan A, Pourfathollah AA, Deyhim M, Hajati E, Goodarzi A.

Int J Hematol Oncol Stem Cell Res. 2018 Jan 1;12(1):35-42.

11.

HLA-DRB1*15:03 and HLA-DRB1*11: useful predictive alleles for alloantibody production in thalassemia patients.

Darvishi P, Sharifi Z, Azarkeivan A, Akbari A, Pourfathollah AA.

Transfus Med. 2019 Jun;29(3):179-184. doi: 10.1111/tme.12531. Epub 2018 Apr 25.

PMID:
29691938
12.

Novel mutations in mitochondrial carrier family gene SLC25A38, causing congenital sideroblastic anemia in Iranian families, identified by whole exome sequencing.

Mehri M, Zarin M, Ardalani F, Najmabadi H, Azarkeivan A, Neishabury M.

Blood Cells Mol Dis. 2018 Jul;71:39-44. doi: 10.1016/j.bcmd.2018.02.002. Epub 2018 Feb 22.

PMID:
29499877
13.

The correlation between cardiac magnetic resonance T2* and left ventricular global longitudinal strain in people with β-thalassemia.

Parsaee M, Akiash N, Azarkeivan A, Alizadeh Sani Z, Amin A, Pazoki M, Samiei N, Jalili MA, Adel MH, Rezaian N.

Echocardiography. 2018 Apr;35(4):438-444. doi: 10.1111/echo.13801. Epub 2018 Feb 4.

PMID:
29399871
14.

Comparison of iron chelation effects of deferoxamine, deferasirox, and combination of deferoxamine and deferiprone on liver and cardiac T2* MRI in thalassemia maior.

Ansari S, Azarkeivan A, Miri-Aliabad G, Yousefian S, Rostami T.

Caspian J Intern Med. 2017 Summer;8(3):159-164. doi: 10.22088/cjim.8.3.159.

15.

Renal Hemosiderosis among Iranian Transfusion Dependent β-Thalassemia Major Patients.

Hashemieh M, Radfar M, Azarkeivan A, Hosseini Tabatabaei SMT, Nikbakht S, Yaseri M, Sheibani K.

Int J Hematol Oncol Stem Cell Res. 2017 Apr 1;11(2):133-138.

16.

Comparison of MicroRNAs Mediated in Reactivation of the γ-Globin in β-Thalassemia Patients, Responders and Non-Responders to Hydroxyurea.

Hojjati MT, Azarkeivan A, Pourfathollah AA, Amirizadeh N.

Hemoglobin. 2017 Mar;41(2):110-115. doi: 10.1080/03630269.2017.1290651.

PMID:
28696844
17.

An enhancer haplotype may influence BCL11A expression levels and the response to hydroxyurea in β-thalassemia patients.

Maroofi N, Azarkeivan A, Banihashemi S, Mohammadparast S, Aghajanirefah A, Banan M.

Pharmacogenomics. 2017 Jul;18(10):995-967. doi: 10.2217/pgs-2017-0019. Epub 2017 Jun 22.

PMID:
28639471
18.

Value of speckle tracking echocardiography for detection of clinically silent left ventricular dysfunction in patients with β-thalassemia.

Parsaee M, Saedi S, Joghataei P, Azarkeivan A, Alizadeh Sani Z.

Hematology. 2017 Oct;22(9):554-558. doi: 10.1080/10245332.2017.1312206. Epub 2017 Apr 12.

PMID:
28399703
19.

T2* Magnetic Resonance Imaging Study of Pancreatic Iron Overload and its Relation With the Diabetic State in Thalassemic Patients.

Hashemieh M, Radfar M, Azarkeivan A, Noghabaei G, Sheibani K.

J Pediatr Hematol Oncol. 2017 Jul;39(5):337-340. doi: 10.1097/MPH.0000000000000767.

PMID:
28085743
20.

Economic Burden of Thalassemia Major in Iran, 2015.

Esmaeilzadeh F, Azarkeivan A, Emamgholipour S, Akbari Sari A, Yaseri M, Ahmadi B, Ghaffari M.

J Res Health Sci. 2016 Summer;16(3):111-115.

21.

Fetal RHD Genotyping from Circulating Cell-Free Fetal DNA in Plasma of Rh Negative Pregnant Women in Iran.

Ahmadi MH, Hantuoshzadeh S, Okhovat MA, Nasiri N, Azarkeivan A, Amirizadeh N.

Indian J Hematol Blood Transfus. 2016 Dec;32(4):447-453. Epub 2015 Nov 6.

22.

A Comparison of Hemostatic Changes in Splenectomized and Nonsplenectomized β-Thalassemia Intermedia Patients.

Hashemieh M, Azarkeivan A, Sheibani K.

J Pediatr Hematol Oncol. 2016 Nov;38(8):636-641.

PMID:
27606436
23.

JAK2V617F Allele Burden Measurement in Peripheral Blood of Iranian Patients with Myeloproliferative Neoplasms and Effect of Hydroxyurea on JAK2V617F Allele Burden.

Ferdowsi S, Ghaffari SH, Amirizadeh N, Azarkeivan A, Atarodi K, Faranoush M, Toogeh G, Shirkoohi R, Vaezi M, Maghsoodlu M, Alimoghaddam K, Ghavamzadeh A, Teimori Naghadeh H.

Int J Hematol Oncol Stem Cell Res. 2016 Apr 1;10(2):70-8.

24.

Evaluation of α-Globin Gene Mutations Among Different Ethnic Groups in Khuzestan Province, Southwest Iran.

Khosravi A, Jalali-Far M, Saki N, Hosseini H, Galehdari H, Kiani-Ghalesardi O, Paridar M, Azarkeivan A, Magaji-Hamid K.

Hemoglobin. 2016;40(2):113-7. doi: 10.3109/03630269.2015.1130720. Epub 2016 Feb 15.

PMID:
26878087
25.

A Large Cohort Study of Genotype and Phenotype Correlations of Beta- Thalassemia in Iranian Population.

Maryami F, Azarkeivan A, Fallah MS, Zeinali S.

Int J Hematol Oncol Stem Cell Res. 2015 Oct 1;9(4):198-202.

26.

First Report of a Dominantly Inherited β-Thalassemia Caused by a Novel Elongated β-Globin Chain.

Farashi S, Rad F, Shahmohammadi B, Imanian H, Azarkeivan A, Najmabadi H.

Hemoglobin. 2016;40(2):102-7. doi: 10.3109/03630269.2015.1135445. Epub 2016 Feb 5.

PMID:
26850598
27.

Correlation between Heart, Liver and Pancreas Hemosiderosis Measured by MRI T2* among Thalassemia Major Patients from Iran.

Azarkeivan A, Hashemieh M, Shirkavand A, Sheibani K.

Arch Iran Med. 2016 Feb;19(2):96-100. doi: 0161902/AIM.006.

28.

Characterization of Homozygous Hb Setif (HBA2: c.283G>T) in the Iranian Population.

Farashi S, Garous NF, Vakili S, Ashki M, Imanian H, Azarkeivan A, Najmabadi H.

Hemoglobin. 2016;40(1):53-5. doi: 10.3109/03630269.2015.1091357. Epub 2015 Nov 16.

PMID:
26574177
29.

Identification of Mutations Causing Aberrant Termination and Deficient Splice Donor Site on the HBA1 Gene.

Farashi S, Vakili S, Garous NF, Ashki M, Forouzesh Pour F, Zeinali F, Rad F, Imanian H, Azarkeivan A, Najmabadi H.

Hemoglobin. 2016;40(1):38-43. doi: 10.3109/03630269.2015.1088456. Epub 2015 Nov 4.

PMID:
26531168
30.

Point mutations which should not be overlooked in Hb H disease.

Farashi S, Bayat N, Vakili S, Faramarzi Garous N, Ashki M, Imanian H, Najmabadi H, Azarkeivan A.

Expert Rev Hematol. 2016 Jan;9(1):107-13. doi: 10.1586/17474086.2016.1107470. Epub 2015 Nov 2.

PMID:
26523940
31.

Copy number variations of six and seven α-globin genes in a family with intermedia and major thalassemia phenotypes.

Farashi S, Vakili S, Faramarzi Garous N, Ashki M, Imanian H, Azarkeivan A, Najmabadi H.

Expert Rev Hematol. 2015 Oct;8(5):693-8. doi: 10.1586/17474086.2015.1075385. Epub 2015 Aug 6. Review.

PMID:
26343893
32.

Mutations on the α2-Globin Gene That May Trigger α(+)-Thalassemia.

Farashi S, Vakili S, Garous NF, Ashki M, Imanian H, Azarkeivan A, Najmabadi H.

Hemoglobin. 2015;39(6):398-402. doi: 10.3109/03630269.2015.1075890. Epub 2015 Sep 2.

PMID:
26329872
33.

Homozygosity for the AATAAA > AATA- - Polyadenylation Site Mutation on the α2-Globin Gene Causing Transfusion-Dependent Hb H Disease in an Iranian Patient: A Case Report.

Farashi S, Garous NF, Ashki M, Vakili S, Zeinali F, Imanian H, Azarkeivan A, Giordano PC, Najmabadi H.

Hemoglobin. 2015;39(5):355-8. doi: 10.3109/03630269.2015.1059850. Epub 2015 Jul 21.

PMID:
26193977
34.

Interaction of an α-Globin Gene Triplication with β-Globin Gene Mutations in Iranian Patients with β-Thalassemia Intermedia.

Farashi S, Bayat N, Faramarzi Garous N, Ashki M, Montajabi Niat M, Vakili S, Imanian H, Zeinali S, Najmabadi H, Azarkeivan A.

Hemoglobin. 2015;39(3):201-6. doi: 10.3109/03630269.2015.1027914. Epub 2015 Jun 18.

PMID:
26084319
35.

Expression analysis of microRNA-125 in patients with polycythemia vera and essential thrombocythemia and correlation with JAK2 allele burden and laboratory findings.

Ferdowsi S, Atarodi K, Amirizadeh N, Toogeh G, Azarkeivan A, Shirkoohi R, Faranoush M, Vaezi M, Alimoghaddam K, Ghavamzadeh A, Naghadeh HT, Ghaffari SH.

Int J Lab Hematol. 2015 Oct;37(5):661-7. doi: 10.1111/ijlh.12381. Epub 2015 May 25.

PMID:
26011312
36.

Hb Dartmouth (HBA2: c.200T>C): An α2-Globin Gene Associated with Hb H Disease in One Homozygous Patient.

Farashi S, Faramarzi Garous N, Ashki M, Vakili S, Zeinali F, Imanian H, Azarkeivan A, Najmabadi H.

Hemoglobin. 2015;39(3):152-5. doi: 10.3109/03630269.2015.1027915. Epub 2015 May 15.

PMID:
25976777
37.

A 21 Nucleotide Duplication on the α1- and α2-Globin Genes Involves a Variety of Hypochromic Microcytic Anemias, From Mild to Hb H Disease.

Farashi S, Faramarzi Garous N, Zeinali F, Vakili S, Ashki M, Imanian H, Najmabadi H, Azarkeivan A, Tamaddoni A.

Hemoglobin. 2015;39(3):196-200. doi: 10.3109/03630269.2015.1030757. Epub 2015 May 15.

PMID:
25976776
38.

Mutation screening of the Krüppel-like factor 1 gene using single-strand conformational polymorphism in a cohort of Iranian β-thalassemia patients.

Zaker-Kandjani B, Namdar-Aligoodarzi P, Azarkeivan A, Najmabadi H, Banan M.

Hemoglobin. 2015;39(1):24-9. doi: 10.3109/03630269.2014.991023. Epub 2015 Jan 13.

PMID:
25583416
39.

RBC alloimmunization and double alloantibodies in thalassemic patients.

Azarkeivan A, Ahmadi MH, Zolfaghari S, Shaiegan M, Ferdowsi S, Rezaei N, Lotfi P.

Hematology. 2015 May;20(4):223-7. doi: 10.1179/1607845414Y.0000000189. Epub 2014 Aug 17.

PMID:
25130935
40.

Seroepidemiology of human T-cell lymphotropic virus among Iranian adult thalassemic patients.

Keshvari M, Hajibeigi B, Azarkeivan A, Keyvani H, Behnava B, Saiedi Hosseini SY, Sharafi H, Alavian SM.

Transfus Med. 2014 Aug;24(4):227-32. doi: 10.1111/tme.12133.

PMID:
25124072
41.

Quality of life in patients with thalassemia major.

Ansari Sh, Baghersalimi A, Azarkeivan A, Nojomi M, Hassanzadeh Rad A.

Iran J Ped Hematol Oncol. 2014;4(2):57-63. Epub 2014 Apr 20.

42.

Characterizing a cohort of α-thalassemia couples collected during screening for hemoglobinopathies: 14 years of an Iranian experience.

Hafezi-Nejad N, Khosravi M, Bayat N, Kariminejad A, Hadavi V, Oberkanins C, Azarkeivan A, Najmabadi H.

Hemoglobin. 2014;38(3):153-7. doi: 10.3109/03630269.2014.909365.

PMID:
24826790
43.

Erythrocytic phosphatidylserine exposure and hemostatic alterations in β-thalassemia intermediate patients.

Zahedpanah M, Azarkeivan A, Aghaieepour M, Nikogoftar M, Ahmadinegad M, Hajibeigi B, Tabatabaiee MR, Maghsudlu M.

Hematology. 2014 Dec;19(8):472-6. doi: 10.1179/1607845413Y.0000000148. Epub 2014 Jan 20.

PMID:
24620948
44.

Peroxisome proliferator-activated receptor-γ Pro12Ala polymorphism and risk of osteopenia in β-thalassemia major patients.

Sahmani M, Gholami A, Azarkeivan A, Darabi M, Ahmadi MH, Sabet MS, Najafipour R.

Hemoglobin. 2013;37(6):564-73. doi: 10.3109/03630269.2013.814035. Epub 2013 Aug 5.

PMID:
23909657
45.

Utility of the multivariate approach in predicting β-thalassemia intermedia or β-thalassemia major types In Iranian patients.

Banan M, Bayat H, Namdar-Aligoodarzi P, Azarkeivan A, Kamali K, Daneshmand P, Zaker-Kandjani B, Najmabadi H.

Hemoglobin. 2013;37(5):413-22. doi: 10.3109/03630269.2013.805418. Epub 2013 Jun 27.

PMID:
23805990
46.

The influence of the BCL11A polymorphism on the phenotype of patients with beta thalassemia could be affected by the beta globin locus control region and/or the Xmn1-HBG2 genotypic background.

Neishabury M, Zamani F, Keyhani E, Azarkeivan A, Abedini SS, Eslami MS, Kakroodi ST, Vesiehsari MJ, Najmabadi H.

Blood Cells Mol Dis. 2013 Aug;51(2):80-4. doi: 10.1016/j.bcmd.2013.02.007. Epub 2013 Mar 28.

PMID:
23541515
47.

Relation between serum ferritin and liver and heart MRI T2* in beta thalassaemia major patients.

Azarkeivan A, Hashemieh M, Akhlaghpoor S, Shirkavand A, Yaseri M, Sheibani K.

East Mediterr Health J. 2013 Aug;19(8):727-32.

48.

Iranian experience of deferasirox (Exjade(®)) in transfusion-dependent patients with iron overload: what is the most effective dose based on serum ferritin levels?

Karimi M, Azarkeivan A, Zareifar S, Cohan N, Bordbar MR, Haghpanah S.

Hematology. 2012 Nov;17(6):367-71. doi: 10.1179/1024533212Z.000000000143.

PMID:
23168076
49.

Hydroxyurea responsiveness in β-thalassemic patients is determined by the stress response adaptation of erythroid progenitors and their differentiation propensity.

Pourfarzad F, von Lindern M, Azarkeivan A, Hou J, Kia SK, Esteghamat F, van Ijcken W, Philipsen S, Najmabadi H, Grosveld F.

Haematologica. 2013 May;98(5):696-704. doi: 10.3324/haematol.2012.074492. Epub 2012 Oct 25.

50.

The XmnI and BCL11A single nucleotide polymorphisms may help predict hydroxyurea response in Iranian β-thalassemia patients.

Banan M, Bayat H, Azarkeivan A, Mohammadparast S, Kamali K, Farashi S, Bayat N, Khani MH, Neishabury M, Najmabadi H.

Hemoglobin. 2012;36(4):371-80. doi: 10.3109/03630269.2012.691147. Epub 2012 Jun 11.

PMID:
22686296

Supplemental Content

Loading ...
Support Center